March 17 (Reuters) - Drugmaker AstraZeneca (AZN.L) has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors. The company has grown its revenue by 17.77% over the last 5 years.

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a buy on AZN stock.

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D ...

CAMBRIDGE, England-- (BUSINESS WIRE)-- AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to the United States, the Times reported on Tuesday, citing multiple sources.

Trading in AstraZeneca 's (AZN 1.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange.

The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI’s de-identified oncology data. This partnership is a big win, matching Tempus AI’s ...

AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative t ...